Abstract. The hepatoprotective effects of ACTIValoe ® N-931 complex, a mixture of Aloe vera and Silybum marianum, against acute and chronic carbon tetrachloride (CCl 4 )-induced liver injuries were investigated. Acute hepatotoxicity was induced by intraperitoneal injection of CCl 4 (50 μl / kg), and ACTIValoe ® N-931 complex at 85, 170, and 340 mg / kg was administered orally 48, 24, and 2 h before and 6 h after injection of CCl 4 . Hepatotoxicity was assessed 24 h after CCl 4 treatment. Liver fibrosis was induced by intraperitoneal injection of CCl 4 for 8 weeks (0.5 ml / kg, twice per week), and mice were treated with ACTIValoe ® N-931 complex at 85, 170, or 340 mg / kg once a day (p.o.). In both acute hepatotoxicity and liver fibrosis, serum aminotransferase levels and lipid peroxidation were increased and the hepatic glutathione content was decreased. These changes were prevented by ACTIValoe 
Introduction
Acute and chronic liver diseases constitute a global concern, but medical treatments for these diseases are often difficult to handle and have limited efficacy. Therefore, considerable efforts to obtain useful herbal medicines from documented medicinal plants for a wide variety of clinical conditions are currently underway. Developing therapeutically effective agents from natural products may reduce the risk of toxicity when the drug is used clinically.
Carbon tetrachloride (CCl 4 ) is a well-known hepatotoxin that is widely used to induce toxic liver injuries in laboratory animals. The hepatic necrosis caused by CCl 4 is thought to involve bioactivation by cytochrome P450 2E1 (CYP2E1), resulting in the formation of trichloromethyl free radicals and reactive oxygen species (ROS), which initiate lipid peroxidation and protein oxidation and damage the hepatocellular membranes (1). This process is followed by the release of inflammatory mediators from activated hepatic macrophages, which are believed to potentiate the CCl 4 -induced hepatic injury. Discrete exposure to CCl 4 results in acute liver injury; continuous exposure to this toxin produces progressive liver injury and fibrosis, eventually causing cirrhosis, portal hypertension, and death (2) .
Aloe vera, which is commonly known as Ghee kanwar (Hindi), is a cactus-like plant that grows in hot, dry climates such as the desert. Its survival in such harsh environments leads to the belief that Aloe vera has wound-healing and antibiotic effects (3) . Aloe vera leaves are used in diseases of the eyes and enlargements of spleen and liver (4) . Moreover, its liver protective function via anti-oxidative and anti-inflammatory effects is well known (5, 6) . Silybum marianum is an herbal supplement used to treat liver and biliary disorders (7) . It has recently been investigated for use as a cytoprotectant, an anti-carcinogen, and a supportive treatment for liver damage from Amanita phalloides poisoning. Silymarin, an active ingredient of Silybum marianum, is a strong antioxidant that promotes liver cell regeneration, reduces blood cholesterol, and helps prevent cancer (8) . In our previous studies, Aloe vera or Silybum marianum alone suppressed the increase in serum aminotransferase activities in both CCl 4 -and D-galactosaminetreated rats. ACTIValoe ® N-931 complex, a mixture of Aloe vera and Silybum marianum, appeared to have a synergistic effect in suppressing the increases in serum aminotransferase activities. Furthermore, ACTIValoe ® N-931 complex protected hepatocytes from hepatotoxicity caused by α-naphthylisothiocyanate and ethionine (9) .
The present study investigated the anti-oxidative and anti-inflammatory properties of ACTIValoe ® N-931 complex against acute CCl 4 liver injury in mice. Its antifibrotic effects in the development of fibrosis after repeated CCl 4 injections were also investigated.
Materials and Methods

Chemicals and reagents
ACTIValoe ® N-931 complex was provided by Univera, Inc., Seoul, Korea. Carbon tetrachloride, glutathione, 2,6-di-tert-butyl-4-methylphenol, 2-thiobarbituric acid, hydrochloride, p-dimethylaminobenzaldehyde, chloramine T hydrate, and p-aminophenol were purchased from Sigma Chemical Co., St. Louis, MO, USA. All other chemicals and reagents used in this study were reagent grade.
Treatment of animals
Male Sprague-Dawley rats (240 -260 g) and male ICR mice (25 -30 4 . The animals were sacrificed by decapitation and blood was collected from the abdominal aorta. The liver was isolated and used immediately to prepare mRNA, which was stored at −75°C for later analysis; part of the left lobe of the liver was used for histological analysis.
Isolation of hepatic microsomal fraction
The excised liver was minced, homogenized with a Teflons pestle homogenizer in 4 volumes of ice-cold 1.15 M KCl for 1 g of the liver, and then centrifuged at 9,000 × g for 60 min. The supernatant was collected and centrifuged at 105,000 × g for 60 min. Microsomal precipitates were resuspended with 4 volumes of 0.1 M phosphate buffer, pH 7.4, for 1 g of the liver microsomes and stored at −75°C until assayed.
Analytical procedures
The levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined by standard spectrophotometric procedures using the ChemiLab ALT and AST assay kits (IVDLab Co., Ltd., Suwon, Korea), respectively. The total glutathione level was measured spectrophotometrically at a wavelength of 412 nm using yeast glutathione reductase and 5,5'-dithio-bis (2-nitrobenzoic acid) as described by Tietze (12) . The oxidized glutathione level was measured using the same method but in the presence of 2-vinylpyridine (13) . The level of reduced glutathione (GSH) was determined by the difference between the total glutathione and oxidized glutathione levels. The steadystate level of malondialdehyde (MDA), which is the end-product of lipid peroxidation, in the liver was determined by measuring the level of thiobarbituric acidreactive substances spectrophotometrically at 535 nm using the method described by Buege and Aust (14) . CYP2E1 activity was determined by 4-hydroxylation of aniline to p-aminophenol (15) The hydroxyproline content in the liver was measured according to the method of Jamall et al. (16) . The serum transforming growth factor-β1 (TGF-β1) concentration was quantified using a commercial TGF-β1 ELISA kit (Biosciences Co., San Diego, CA, USA). Protein concentration was estimated by the dye binding assay of Bradford (17) .
Total RNA extraction and reverse transcriptionpolymerase chain reaction (RT-PCR)
Total RNA was extracted from liver tissue using TRIzol-reagent (GibcoBRL, Grand Island, NY, USA) according to the manufacturer's protocol. First strand cDNA was synthesized by reverse transcription of total RNA using oligo dT-adaptor primer and AMV Reverse Transcriptase. The PCR reaction was performed with a diluted cDNA sample in a 10 μl reaction volume. The final reaction concentrations were 10 pmol primers, 2.5 mM MgCl 2 , 1 mM dNTP mixture, 1 μl 10 × RNA PCR buffer, and 0.5 U Ex Taq-DNA polymerase per reaction. Table 1 lists the gene-specific primers used. All PCRs involved an initial denaturation step at 94°C for 5 min and a final extension at 72°C for 5 min in the GeneAmp 2700 thermocycler (Perkin-Elmer, Inc., Waltham, MA, USA). The cycling conditions for PCR amplification were as follows: 28 cycles of 94°C (30 s 
Histopathological analysis
Liver slices were prepared from a portion of the left lobe and fixed immediately in 10% formalin-buffered phosphate solution, embedded in paraffin, and sectioned at 5-μm thickness. Serial sections were stained with hematoxylin and eosin (H&E) to evaluate portal inflammation, inflammatory cell infiltration, centrizonal necrosis, liver cell dysplasia, ballooning degeneration, vascular congestion, fatty change, and fibrosis. The sections were examined in a blind manner under an Olympus CKX 41 microscope (Olympus Optical Co., Ltd., Tokyo).
Statistical analyses
All results are presented as the mean ± S.E.M. Oneway analysis of variance (ANOVA) followed by Student-Neuman-Keuls test was used to determine the significance of the differences between the experimental groups. A P-value <0.05 was considered significant. 170 mg / kg ( Table 2) . No significant effects on serum aminotransferase activities, MDA level, and hepatic glutathione content were observed in mice treated with the ACTIValoe ® N-931 complex at 42.5 mg / kg (data not shown). The CYP2E1 activity markedly increased in the CCl 4 -treated group to levels about 318% of those seen in microsomes from the control. This increase was attenuated by ACTIValoe ® N-931complex at 85, 170, and 340 mg / kg (Fig. 1) . The histopathological features of normal liver lobular architecture and cell structure are shown in Fig. 2 for the control livers. However, liver exposed to CCl 4 exhibited multiple, extensive areas of portal inflammation, centrizonal necrosis, and vascular degradation. These histopathological changes were attenuated by the ACTIValoe ® N-931 complex. The TNF-α, iNOS, and COX-2 mRNA expressions were significantly higher in CCl 4 -treated mice than in the controls. The increases were significantly suppressed by the administration of ACTIValoe ® N-931 complex (Fig. 3) . The administration of CCl 4 increased the content of hydroxyproline to 2.0 times that of the control (Fig. 4) . This increase was significantly attenuated by treatment (Table 3) . As shown in Fig. 6 , the level of TGF-β1 was markedly elevated to 2.8 times that of the control, and this increase was significantly attenuated by ACTIValoe ® N-931 complex at 85 and 170 mg / kg. The TIMP-1 mRNA expression in the CCl 4 -injected group was 1200-fold higher than that in the control group. The increase in TIMP-1 mRNA level was significantly suppressed by ACTIValoe ® N-931 complex at 170 and 340 mg / kg (Fig. 7) .
Results
Effect of ACTIValoe
Discussion
In the present study, the hepatoprotective effects of ACTIValoe ® N-931 complex in acute and chronic liver injury models were investigated. We first examined the Many hepatotoxicants including CCl 4 , nitrosamines, and polycyclic aromatic hydrocarbons require metabolic activation, particularly by liver CYP enzymes to form reactive toxic metabolites, which in turn cause liver injury in experimental animals and humans. Alterations in the activity of CYP2E1 can affect the susceptibility to hepatic injury from CCl 4 . The trichloromethyl radical formed during the metabolism of CCl 4 is capable of binding to lipids, and this binding initiates lipid peroxidation and liver damage (18) . GSH constitutes the first line of defense against free radicals and is a critical determinant of tissue susceptibility to oxidative damage. In this study, the ACTIValoe ® N-931 complex exhibited protective effects by impairing CCl 4 -mediated oxidative stress through decreased production of free radical derivatives, as evidenced by the decreased CYP2E1 activity and MDA level. Furthermore, the ACTIValoe ® N-931 complex attenuated hepatic glutathione depletion 24 h after CCl 4 injection. The increase in the hepatic glutathione level in ACTIValoe ® N-931 complex-treated mice could be due either to its effect on the de novo synthesis of glutathione, its regeneration, or both. These results suggest that the antioxidant properties may be one mechanism by which the ACTIValoe ® N-931 complex protects against CCl 4 -mediated liver damage.
The liver is a major inflammatory organ and inflammatory processes contribute to a number of pathological events after exposure to various hepatotoxins. Kupffer cells release pro-inflammatory mediators either in response to necrosis or in direct response to an activated hepatotoxin; these pro-inflammatory mediators are believed to aggravate CCl 4 -induced hepatic injury (19) .
TNF-α is a major endogenous mediator of hepatotoxicity in several experimental liver injuries (20) through its direct cytotoxicity (21) , nitric oxide production (22) , and the triggering of an inflammatory cascade. It has been well established that both oxidative stress and abnormal production of cytokines, especially TNF-α, play important etiological roles in the pathogenesis of alcoholic liver disease. Acute ethanol administration to mice has been found to induce hepatic TNF-α production and mRNA expression and down-regulated TNF-α production by antioxidants was paralleled by attenuated hepatic lipid peroxidation, steatosis, and liver injury (23) . Nitric oxide, which is produced by iNOS, is a highly reactive oxidant that plays a role in a number of physiological processes such as vasodilation, neurotransmission, and nonspecific host defense (24) . As nitric oxide has a range of effects on a variety of biological processes, it is unclear if it is beneficial or detrimental in the liver injury induced by hepatotoxins. Previous studies reported that the induction of COX in the inflammatory response is a secondary effect of CCl 4 -induced hepatotoxicity (25) . COX-2, the mitogeninducible isoform of COX, is induced in macrophages by several pro-inflammatory stimuli such as cytokines and growth factors, leading to COX-2 expression and the subsequent release of prostaglandins (26) . This study confirmed a significant increase in the TNF-α, iNOS, and COX-2 mRNA expressions in the liver after CCl 4 administration; these increases were attenuated by treatment with the ACTIValoe Hepatic fibrosis is a consequence of various chronic liver diseases caused by hepatitis viruses, drugs, alcohol, parasites, and autoimmune mechanisms. Studies in animal models of hepatic fibrosis show that extracellular matrix components accumulate in interstitial regions of the liver around central veins or in the portal tract. There are now several animal models of liver fibrosis, among which the CCl 4 -induced rat liver fibrosis model has been extensively investigated and applied. Normally, hepatic stellate cells are quiescent, but they become activated following liver injury. These activated hepatic stellate cells are primarily responsible for the excess production of extracellular matrix (28) . Thus, reduction of extracellular matrix production by activated hepatic stellate cells is crucial for the prevention of fibrogenesis. In this study, liver fibrosis was observed as significant histological changes and significant increases in hydroxyproline content in an assessment of liver collagen content. Administration of CCl 4 to rats twice a week for 8 weeks caused a variety of histological changes in the liver including extensive areas of fatty change and gross necrosis, broad infiltration of lymphocytes, and Kupffer cell hyperplasia. These changes were significantly attenuated by the ACTIValoe A large body of evidence suggests that oxidative stress is a major mechanism in the etiology of fibrosis (29) . Excess ROS play a major mediatory role in inducing the synthesis of fibrillar extracellular matrix (30) . The anti-fibrotic effect of ACTIValoe ® N-931 complex can also be ascribed to the suppression of lipid peroxidation as well as its propagation in the liver because ACTIValoe ® N-931 complex attenuates the CCl 4 -induced increase in hepatic MDA content. Severe liver damage is followed by a phase of liver repair wherein surrounding hepatocytes proliferate and extracellular matrix synthesis increases. During liver repair, TGF-β1 limits the proliferative response of hepatocytes and increases the production of collagen and other extracellular matrix proteins (31) . Consistent with these findings, the present study demonstrated that, during the development of liver fibrosis, TGF-β1 levels were markedly elevated and these increases were significantly attenuated by ACTIValoe ® N-931 complex. Matrix metalloproteinases (MMPs) comprise a family of zinc-dependent enzymes that specifically degrade extracellular matrix components (32) . Among them, the key enzymes in the degradation of fibrillar collagens are MMP-1 in humans and MMP-13 in rodents (33) . However, during fibrogenesis, the expression of MMP-1 or MMP-13 is very limited, whereas that of MMP-2 increases (34). The activity of MMPs is regulated by TIMP. TIMP-1 is produced by Kupffer cells, hepatic stellate cells, and myofibroblasts in liver, but it is mainly produced by activated hepatic stellate cells. Injured liver tissue expresses more TIMP-1, which in turn causes interstitial fibrils to accumulate (35) . In our model, there were no significant changes in the expression of MMP-2 mRNA in any of the experimental groups (data not shown). However, there was increased expression of TIMP-1 mRNA in liver following repeated injection of CCl 4 . We observed that increased TIMP-1 mRNA levels were significantly attenuated by ACTIValoe ® N-931 complex. These results suggest that the anti-fibrotic effect of ACTIValoe ® N-931 complex is related to increased removal of deposited collagen, that is, enhanced collagenolytic activity due to decreased TIMP-1 levels.
Several studies have been reported that TGF-β1 stimulates the production of TIMP-1 mRNA (36) . It also acts synergistically with other cytokines such as epidermal growth factor, basic fibroblast growth factor, and embryonal carcinoma-derived growth factor to increase the level of expression of TIMP-1 mRNA (37). In our results, ACTIValoe ® N-931 complex at 85 mg / kg did not suppress the TIMP-1 mRNA levels, whereas it attenuated the TGF-β1 levels in CCl 4 -induced chronic hepatotoxicity. This result may involve other factors such as epidermal growth factor, basic fibroblast growth factor, and embryonal carcinoma-derived growth factor.
In conclusion, the hepatoprotective and anti-fibrotic activity of ACTIValoe ® N-931 complex could be attributed to its mechanistic intervention in several cellular events, providing beneficial effects, most importantly, by 1) attenuating oxidative stress, 2) preventing the inflammatory response, and 3) enhancing collagenolytic activity. This study provides evidence that ACTIValoe ® N-931 complex could be used to prevent hepatocellular damage and liver fibrosis.
